Home Cart Sign in  
Chemical Structure| 1429749-41-6 Chemical Structure| 1429749-41-6

Structure of Thiomyristoyl
CAS No.: 1429749-41-6

Chemical Structure| 1429749-41-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Thiomyristoyl is an inhibitor of Sirt2 and Sirt1 with IC50 of 28 nM, 98 μM.

Synonyms: TM

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Thiomyristoyl

CAS No. :1429749-41-6
Formula : C34H51N3O3S
M.W : 581.85
SMILES Code : O=C(OCC1=CC=CC=C1)N[C@@H](CCCCNC(CCCCCCCCCCCCC)=S)C(NC2=CC=CC=C2)=O
Synonyms :
TM
MDL No. :MFCD30738003
InChI Key :CJQGLLUJIVNREL-HKBQPEDESA-N
Pubchem ID :126843233

Safety of Thiomyristoyl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of Thiomyristoyl

epigenetics

Isoform Comparison

Biological Activity

Target
  • SIRT2

    SIRT2, IC50:28 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 25 µM 72 h To evaluate the effect of TM on the viability of MDA-MB-231 cells, the results showed that TM significantly inhibited the viability of MDA-MB-231 cells. PMC4811675
MDA-MB-468 25 µM 72 h To evaluate the effect of TM on the viability of MDA-MB-468 cells, the results showed that TM significantly inhibited the viability of MDA-MB-468 cells. PMC4811675
MCF-7 25 µM 72 h To evaluate the effect of TM on the viability of MCF-7 cells, the results showed that TM significantly inhibited the viability of MCF-7 cells. PMC4811675
HEK293T cells 0, 5, 10, 50, 100, 200 μM To test the effect of different concentrations of BHJH-TM3 on TNF α fatty acylation levels. Results showed that the fluorescent labelling of TNF α increased significantly with increasing concentrations of BHJH-TM3, indicating effective inhibition of Sirt6 in cells. PMC4161628
HEK293T cells 200 μM To test the inhibitory effect of Thiomyristoyl peptides on Sirt6 and the impact on TNF α fatty acylation levels. Results showed that Thiomyristoyl peptides significantly increased the fatty acylation level of TNF α, indicating effective inhibition of Sirt6 in cells. PMC4161628

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MDA-MB-231 xenograft model Intraperitoneal injection 1.5 mg Daily for 30 days To evaluate the anti-tumor effect of TM in the MDA-MB-231 xenograft model, the results showed that TM significantly inhibited tumor growth. PMC4811675

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.59mL

1.72mL

0.86mL

17.19mL

3.44mL

1.72mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories